ClinicalTrials.gg
TerminatedNCT03059355CERESUpdated Nov 8, 2022Results posted

Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression.

A Phase 1/2 interventional study of UCMSCs and BMMSCs in Endothelial Dysfunction, Metabolic Syndrome and Chronic Inflammation, sponsored by Joshua M Hare. Terminated at 1 site in United States. Open to participants aged 21 Years to 95 Years. Per ClinicalTrials.gov, last updated 2022-11-08.

Sponsored by Joshua M Hare · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
COVID-19 Pandemic and lack of funding

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
21 Years to 95 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 578 studies in Metabolic Syndrome with a site in United States — 62 open to participants now, 84 under way, 3 of them phase 3. Metabolic Syndrome · United States.

Enrollment
433rd of 490
14 · median 48
Started
2018
with 28 others
Phase 1/2
12 of 578
2 open now
Registered
355th of 578
by date

Among the 578 studies in Metabolic Syndrome with a site in United States, this one is the 433rd largest by enrollment of the 490 interventional ones that give a count, is one of 29 that started in 2018, is one of 12 in phase 1/2, and was the 355th registered.

Metabolic Syndrome

2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

62 of the 578 studies in Metabolic Syndrome with a site in United States are open now. Recruiting first, the newest first:

57 more — sign in →

All 62 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.

This study: 21 Years to 95 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 578 studies in Metabolic Syndrome with a site in United States, or all of them as a file.
02

Study summary

This study is to compare the safety and efficacy of UCMSCs and BMMSCs administered intravenously in patients to evaluate cytokine suppression in patients with chronic inflammation. Cells administered via intravenous infusion (IV) and will be tested in 37 patients in two phases (Pilot and Randomized).

03

Conditions studied

  • Endothelial Dysfunction
  • Metabolic Syndrome
  • Chronic Inflammation

Browse trials for

04

Who can participate

Ages eligible
21 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide written
  • Subjects age > 21 and \< 95 years at the time of signing the Informed Consent Form.
  • Each subject must have endothelial dysfunction.

Endothelial dysfunction Criteria:

Impaired flow-mediated vasodilation (FMD \<7%)

  • At the time of enrollment, each subject must meet at least 3 out of the 5 criteria under the harmonized definition of the metabolic syndrome, consisting of the following:
  • Waist circumference - US defined: ≥ 102 cm (males) or ≥ 88 cm (females)
  • Elevated triglycerides - ≥ 150 mg/dL (1.7 mM)
  • Reduced HDL-C - Males: \<40 mg/dL (1.0 mM) Females: \<50 mg/dL (1.3 mM)
  • Elevated blood pressure - Systolic ≥ 130 mm Hg and/or Diastolic ≥ 85 mm Hg
  • Elevated fasting glucose - ≥ 100 mg/dL

Exclusion criteria

Exclusion Criteria:

  • Be a female who is pregnant, nursing, or of while not practicing effective methods. Female subjects must undergo a blood or urine pregnancy test at screening and within 36 hours prior to infusion.
  • Inability to perform any of the assessments required for endpoint analysis.
  • Active listing (or expected future listing) for transplant of any organ.
  • abnormal screening laboratory values, as determined by the P.I.
  • Serious comorbid illness or any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the subject or preclude successful completion of the study.
  • Have known allergies to penicillin or streptomycin.
  • to dimethyl sulfoxide (DMSO).
  • Be a solid organ transplant recipient. This does not include prior cell-based therapy (>12 months prior enrollment) bone, skin, ligament, tendon or corneal grafting. Have a history of organ or cell transplant rejection.
  • Have a clinical history of within 3 years (i.e., subjects with prior malignancy must be disease free for 3 years), except curatively- treated basal cell carcinoma, squamous cell carcinoma, melanoma in situ or cervical carcinoma, if recurrence occurs.
  • Have a non-pulmonary condition that limits lifespan to \< 1 year.
  • History of drug abuse (illegal "street" drugs except marijuana, or prescription medications not being used appropriately for a pre-existing medical condition) or alcohol abuse (≥ 5 drinks/day for ˃ 3 months), or documented medical, occupational, or legal problems arising from the use of alcohol or drugs within the past 24 months.
  • Be serum positive for , surface antigen or Viremic , and/or Syphilis.
  • Be currently participating (or participated within the previous 30 days) in an therapeutic or device trial.
  • Patients with \<45% (heart failure patients).
  • \< or equal to 35 (chronic kidney disease stage 3 or higher).
  • Liver disease (elevated Liver Function Tests greater than 3x normal limit).
  • Advanced pulmonary disease (requiring home oxygen and/or less than 1 expected life span).
  • Proliferative diabetic retinopathy
  • greater than 7.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Pilot Phase: Group 1 (UCMSCs - 20 million)

    Three (3) subjects will be treated with a single administration of 2 x 10\^7 (20 million) UCMSCs delivered via peripheral intravenous infusion.

    Biological: UCMSCs

  • Experimental
    Pilot Phase: Group 3 (UCMSCs - 100 million)

    Three (3) subjects will be treated with a single IV administration of 1 x 10\^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.

    Biological: UCMSCs

  • Experimental
    Pilot Phase: Group 2 (BMMSCs - 20 million)

    Three (3) subjects will be treated with a single IV administration of 2 x 10\^7 (20 million) BMMSCs delivered via peripheral intravenous infusion.

    Biological: BMMSCs

  • Experimental
    Pilot Phase: Group 4 (BMMSCs -100 million)

    Three (3) subjects will be treated with a single IV administration of 1 x 10\^8 (100 million) BMMSCs delivered via peripheral intravenous infusion.

    Biological: BMMSCs

  • Experimental
    Group A (UCMSCs - 100 million)

    Participants randomized to receive a single administration of 1 x 10\^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.

    Biological: UCMSCs

  • Experimental
    Group B (BMMSCs - 100 million)

    Participants randomized to receive a single administration of 1 x 10\^8 (100 million) BMMSC delivered via peripheral intravenous infusion.

    Biological: BMMSCs

  • Placebo comparator
    Group C (Placebo)

    Participants randomized to receive a single administration of placebo via peripheral intravenous infusion.

    Other: Placebo

Interventions

  • BiologicalUCMSCs

    Allogeneic Umbilical Cord Tissue derived MSCs (UCMSCs)

  • BiologicalBMMSCs

    Bone Marrow derived Mesenchymal Stem Cells (BMMSCs)

  • OtherPlacebo

    a single administration of placebo delivered via peripheral intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Number of Treatment-Emergent Serious Adverse Events (TE-SAEs)

    Number of treatment-emergent serious adverse events (SAE) (at one-month post infusion), defined as the composite of: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities, determined per the Investigator's judgment.

    Time frame: one month post infusion

Secondary outcomes

  1. Cytokine Levels

    Cytokine levels including the following panel of inflammatory and angiogenic markers: Interleukin-1 (IL-1), Interleukin-6 (IL-6), Tumor Necrosis Factor alpha (TNFα), and Vascular Endothelial Growth Factor (VEGF), \& Stromal Cell Derived Factor (SDF-1a) levels from serum/plasma samples all measured in pg/mL.

    Time frame: at Baseline, at Week 2, at Month 1, at Month 3, and at Month 6

  2. hsCRP Levels

    values at baseline and follow up for the following inflammatory marker: Serum High sensitivity C-Reactive Protein (hsCRP) in mg/L.

    Time frame: at Baseline, at Week 2, at Month 1, at Month 3, and at Month 6

  3. Stem Cell Factor (SCF) Levels

    SCF levels from serum/plasma samples measured in units of mg/mL

    Time frame: at Baseline, at Week 2, at Month 1, at Month 3, and at Month 6

  4. Endothelial Progenitor Cell-Colony Forming Units (EPC-CFUs)

    Endothelial function will be reported as the change in Endothelial Progenitor Cell Colony Forming Unit (EPC-CFU) assessed via blood sample assay

    Time frame: at Baseline, and at 3 months

  5. Flow Mediated Diameter Percentage (FMD%)

    FMD% will be assessed using brachial artery ultrasound

    Time frame: at Baseline and at Month 3

07

Results

Posted Nov 8, 2022
Limitations and caveats
Funding timeline was not met due to the coronavirus disease 2019 (COVID-19) pandemic. No additional funding was provided, therefore the study had to be terminated early.

Participant flow

No subjects had been randomized to Group A or C at the time of trial termination.

Participant flow — Overall Study
MilestonePilot Phase: Group 1 (UCMSCs - 20 Million)Pilot Phase: Group 2 (BMMSCs - 20 Million)Pilot Phase: Group 3 (UCMSCs - 100 Million)Pilot Phase: Group 4 (BMMSCs -100 Million)Group A (UCMSCs - 100 Million)Group B (BMMSCs - 100 Million)Group C (Placebo)
Started3333020
Completed3333020
Not completed0000000

Outcome measures

PrimaryNumber of Treatment-Emergent Serious Adverse Events (TE-SAEs)

Number of treatment-emergent serious adverse events (SAE) (at one-month post infusion), defined as the composite of: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities, determined per the Investigator's judgment.

Time frame:
one month post infusion
Reported as:
Number · Events
Number of Treatment-Emergent Serious Adverse Events (TE-SAEs)
EventsPilot Phase: Group 1 (UCMSCs - 20 Million)Pilot Phase: Group 2 (BMMSCs - 20 Million)Pilot Phase: Group 3 (UCMSCs - 100 Million)Pilot Phase: Group 4 (BMMSCs -100 Million)Group A (UCMSCs - 100 Million)Group B (BMMSCs - 100 Million)Group C (Placebo)
Number of Treatment-Emergent Serious Adverse Events (TE-SAEs)0000—0—
SecondaryCytokine Levels

Cytokine levels including the following panel of inflammatory and angiogenic markers: Interleukin-1 (IL-1), Interleukin-6 (IL-6), Tumor Necrosis Factor alpha (TNFα), and Vascular Endothelial Growth Factor (VEGF), \& Stromal Cell Derived Factor (SDF-1a) levels from serum/plasma samples all measured in pg/mL.

Time frame:
at Baseline, at Week 2, at Month 1, at Month 3, and at Month 6
Reported as:
Mean · pg/mL
Cytokine Levels
pg/mLPilot Phase: Group 1 (UCMSCs - 20 Million)Pilot Phase: Group 2 (BMMSCs - 20 Million)Pilot Phase: Group 3 (UCMSCs - 100 Million)Pilot Phase: Group 4 (BMMSCs -100 Million)Group A (UCMSCs - 100 Million)Group B (BMMSCs - 100 Million)Group C (Placebo)
IL-6 Baseline5.7 ± 4.82.7 ± 1.83.2 ± 2.52.9 ± 1.9—1.2 ± 0.6—
IL-6 Week 25.8 ± 5.23.4 ± 1.05.4 ± 6.73.7 ± 2.3—1.4 ± 0.4—
IL-6 Month 15.4 ± 3.92.8 ± 1.02.5 ± 1.02.1 ± 0.9—1.3—
IL-6 Month 38.4 ± 4.52.5 ± 1.21.9 ± 0.62.3 ± 1.0———
IL-6 Month 62.9 ± 2.23.2 ± 1.33.8 ± 3.02.2 ± 0.4———
TNFa Baseline1.7 ± 0.41.6 ± 0.41.6 ± 0.82.1 ± 0.5—1.1 ± 0.2—
TNFa Week 21.9 ± 0.81.5 ± 0.61.5 ± 0.62.1 ± 0.7—0.9 ± 0.3—
TNFa Month 11.7 ± 1.11.5 ± 0.32.0 ± 0.92.2 ± 0.8—0.7—
TNFa Month 32.2 ± 1.71.2 ± 0.51.8 ± 1.01.8 ± 0.5—0.7—
TNFa Month 61.5 ± 0.61.4 ± 0.31.4 ± 0.31.0 ± 0.5—0.5—
VEGF Baseline13.5 ± 4.819.2 ± 925.1 ± 1413.5 ± 1.7———
VEGF Month 315.3 ± 316.5 ± 12.415.5 ± 6.49.5 ± 1.8———
SecondaryhsCRP Levels

values at baseline and follow up for the following inflammatory marker: Serum High sensitivity C-Reactive Protein (hsCRP) in mg/L.

Time frame:
at Baseline, at Week 2, at Month 1, at Month 3, and at Month 6
Reported as:
Mean · mg/L
hsCRP Levels
mg/LPilot Phase: Group 1 (UCMSCs - 20 Million)Pilot Phase: Group 2 (BMMSCs - 20 Million)Pilot Phase: Group 3 (UCMSCs - 100 Million)Pilot Phase: Group 4 (BMMSCs -100 Million)Group A (UCMSCs - 100 Million)Group B (BMMSCs - 100 Million)Group C (Placebo)
Baseline2.0 ± 1.613.0 ± 19.21.4 ± 0.43.2 ± 1.9—0.5 ± 0.3—
Week 29.2 ± 14.45.7 ± 6.01.7 ± 1.44.3 ± 3.3—0.6 ± 0.3—
Month 110.7 ± 16.04.6 ± 4.02.1 ± 1.42.9 ± 1.2—0.6—
Month 35.0 ± 3.44.7 ± 5.12.7 ± 2.93.4 ± 1.3—0.9—
Month 61.6 ± 1.15.4 ± 7.02.6 ± 1.22.1—0.6—
SecondaryStem Cell Factor (SCF) Levels

SCF levels from serum/plasma samples measured in units of mg/mL

Time frame:
at Baseline, at Week 2, at Month 1, at Month 3, and at Month 6

No measurements were reported for this outcome.

SecondaryEndothelial Progenitor Cell-Colony Forming Units (EPC-CFUs)

Endothelial function will be reported as the change in Endothelial Progenitor Cell Colony Forming Unit (EPC-CFU) assessed via blood sample assay

Time frame:
at Baseline, and at 3 months
Reported as:
Mean · Colony Forming Units per Well
Endothelial Progenitor Cell-Colony Forming Units (EPC-CFUs)
Colony Forming Units per WellPilot Phase: Group 1 (UCMSCs - 20 Million)Pilot Phase: Group 2 (BMMSCs - 20 Million)Pilot Phase: Group 3 (UCMSCs - 100 Million)Pilot Phase: Group 4 (BMMSCs -100 Million)Group A (UCMSCs - 100 Million)Group B (BMMSCs - 100 Million)Group C (Placebo)
Baseline15.0 ± 14.50.8 ± 0.92.3 ± 3.14.8 ± 6.6—0.6 ± 0.6—
Month 320.4 ± 20.81.3 ± 1.113.2 ± 13.61.9 ± 2.0———
SecondaryFlow Mediated Diameter Percentage (FMD%)

FMD% will be assessed using brachial artery ultrasound

Time frame:
at Baseline and at Month 3
Reported as:
Mean · percentage of change in brachial artery
Flow Mediated Diameter Percentage (FMD%)
percentage of change in brachial arteryPilot Phase: Group 1 (UCMSCs - 20 Million)Pilot Phase: Group 2 (BMMSCs - 20 Million)Pilot Phase: Group 3 (UCMSCs - 100 Million)Pilot Phase: Group 4 (BMMSCs -100 Million)Group A (UCMSCs - 100 Million)Group B (BMMSCs - 100 Million)Group C (Placebo)
Baseline3.6 ± 2.04.1 ± 1.13.6 ± 0.83.1 ± 1.4—5.0 ± 0.8—
Month 33.5 ± 1.95.4 ± 3.75.4 ± 0.54.0 ± 0.8———

Adverse events

Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pilot Phase: Group 1 (UCMSCs - 20 Million)0/3 (0%)1/3 (33.3%)3/3 (100%)
Pilot Phase: Group 2 (BMMSCs - 20 Million)0/3 (0%)0/3 (0%)2/3 (66.7%)
Pilot Phase: Group 3 (UCMSCs - 100 Million)0/3 (0%)0/3 (0%)2/3 (66.7%)
Pilot Phase: Group 4 (BMMSCs -100 Million)0/3 (0%)0/3 (0%)3/3 (100%)
Group A (UCMSCs - 100 Million)———
Group B (BMMSCs - 100 Million)0/2 (0%)0/2 (0%)1/2 (50%)
Group C (Placebo)———
Most frequent serious events
Most frequent serious events
EventPilot Phase: Group 1 (UCMSCs - 20 Million)Pilot Phase: Group 2 (BMMSCs - 20 Million)Pilot Phase: Group 3 (UCMSCs - 100 Million)Pilot Phase: Group 4 (BMMSCs -100 Million)Group A (UCMSCs - 100 Million)Group B (BMMSCs - 100 Million)Group C (Placebo)
Esophageal PerforationGastrointestinal disorders1/30/30/30/3—0/2—
SepsisInfections and infestations1/30/30/30/3—0/2—
Most frequent other events
Showing 10 of 45
Most frequent other events
EventPilot Phase: Group 1 (UCMSCs - 20 Million)Pilot Phase: Group 2 (BMMSCs - 20 Million)Pilot Phase: Group 3 (UCMSCs - 100 Million)Pilot Phase: Group 4 (BMMSCs -100 Million)Group A (UCMSCs - 100 Million)Group B (BMMSCs - 100 Million)Group C (Placebo)
Upper Respiratory InfectionInfections and infestations3/32/30/32/3—0/2—
AnemiaBlood and lymphatic system disorders2/30/30/30/3—0/2—
Squamous Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/30/30/30/3—0/2—
Toe FractureInjury, poisoning and procedural complications0/30/30/30/3—1/2—
Monoclonal Gammopathy of Uncertain SignificanceBlood and lymphatic system disorders1/30/30/30/3—0/2—
ThrombocytopeniaBlood and lymphatic system disorders1/30/30/30/3—0/2—
LeukopeniaBlood and lymphatic system disorders0/30/31/30/3—0/2—
Congestive Heart FalureCardiac disorders1/30/30/30/3—0/2—
Atrial FibrillationCardiac disorders1/30/30/30/3—0/2—
Periorbital HematomaEye disorders1/30/30/30/3—0/2—

Baseline characteristics

Randomized phase of the study was terminated after only 2 participants. No subjects were allocated to Group A or Group C in the randomized phase of the trial.

Age, Continuous
Age, Continuous(years)Pilot Phase: Group 1 (UCMSCs - 20 Million)Pilot Phase: Group 2 (BMMSCs - 20 Million)Pilot Phase: Group 3 (UCMSCs - 100 Million)Pilot Phase: Group 4 (BMMSCs -100 Million)Group A (UCMSCs - 100 Million)Group B (BMMSCs - 100 Million)Group C (Placebo)Total
Mean85.67 ± 5.1362.00 ± 8.7261.67 ± 12.960.67 ± 12.42—52 ± 12.73—65.17 ± 13.29
Sex: Female, Male
Sex: Female, Male(Participants)Pilot Phase: Group 1 (UCMSCs - 20 Million)Pilot Phase: Group 2 (BMMSCs - 20 Million)Pilot Phase: Group 3 (UCMSCs - 100 Million)Pilot Phase: Group 4 (BMMSCs -100 Million)Group A (UCMSCs - 100 Million)Group B (BMMSCs - 100 Million)Group C (Placebo)Total
Female11010003
Male223202011
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pilot Phase: Group 1 (UCMSCs - 20 Million)Pilot Phase: Group 2 (BMMSCs - 20 Million)Pilot Phase: Group 3 (UCMSCs - 100 Million)Pilot Phase: Group 4 (BMMSCs -100 Million)Group A (UCMSCs - 100 Million)Group B (BMMSCs - 100 Million)Group C (Placebo)Total
Hispanic or Latino01120105
Not Hispanic or Latino32210109
Unknown or Not Reported00000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pilot Phase: Group 1 (UCMSCs - 20 Million)Pilot Phase: Group 2 (BMMSCs - 20 Million)Pilot Phase: Group 3 (UCMSCs - 100 Million)Pilot Phase: Group 4 (BMMSCs -100 Million)Group A (UCMSCs - 100 Million)Group B (BMMSCs - 100 Million)Group C (Placebo)Total
American Indian or Alaska Native00000000
Asian10000001
Native Hawaiian or Other Pacific Islander00000000
Black or African American00000101
White233201011
More than one race00000000
Unknown or Not Reported00010001
08

Study locations

1 site
  • ISCI / University of Miami Miller School of Medicine
    Miami, Florida 33136, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Mar 2020, 23 months.

Results were first posted in Nov 2022, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2017
First posted
Feb 23, 2017
StartActual
Apr 12, 2018
Primary completionActual
Mar 23, 2020
CompletionActual
Feb 11, 2021
Results first posted
Nov 8, 2022
Last update
Nov 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03059355
Lead sponsor
Joshua M Hare
Collaborators
The Marcus Foundation
Responsible party
Joshua M Hare (Director of ISCI, Louis Lemberg Professor of Medicine, University of Miami) — Sponsor-investigator
First posted
Feb 23, 2017
Start date
Apr 12, 2018
Primary completion
Mar 23, 2020
Completion
Feb 11, 2021
Results posted
Nov 8, 2022
Last update
Nov 8, 2022

Study contacts

Joshua M Hare, MD
principal investigator · ISCI / University of Miami Miller School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion